iTeos Therapeutics has two programs: what it means for iTeos Therapeutics stock

Published on 10/02/2026 at 04:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

iTeos has two clinical-stage programs, belrestotug and EOS-984. For iTeos Therapeutics stock, studies span Phase 3 planned and Phase 2 active.

ITOS, US46565G1040, Illustration mit AI erstellt.

iTeos Therapeutics (ISIN US46565G1040) lists two clinical-stage programs, belrestotug and EOS-984, on its pipeline page, according to iTeos Therapeutics. The company is developing targeted immunotherapies for people living with cancer, giving the pipeline a central role in the stock story.

Two programs define the pipeline

Belrestotug, also known as EOS-448, is the more advanced program. The company page lists a Phase 2 active trial in combination with dostarlimab for non-small cell lung cancer, a second Phase 2 active study in head and neck cancer, and a Phase 3 planned study in non-small cell lung cancer, according to iTeos Therapeutics.

The second named clinical-stage program, EOS-984, is listed in a planned Phase 1 study for advanced malignancies. The site also lists EOS-215 in a planned Phase 1 study, expanding the visible pipeline beyond the two programs highlighted in the company overview.

Clinical stages shape the risk profile

The stage mix points to a development-driven investment case. Phase 2 and planned Phase 3 work can create more meaningful clinical milestones than early research, but each program still depends on trial execution, regulatory progress and data quality.

For investors, the distinction between active and planned studies is important. Belrestotug already has active Phase 2 trials, while the listed Phase 3 program remains planned; EOS-984 and EOS-215 are positioned earlier in development. Those different stages create separate timing and execution factors across the pipeline.

Nasdaq listing and oncology focus

Investing.com identifies iTeos Therapeutics as NASDAQ-listed under the ticker ITOS and assigns ISIN US46565G1040 to the company. Its business classification is biotechnology within healthcare, consistent with the company description of immuno-oncology research and development.

The company website also lists prior corporate announcements, including an agreement to be acquired by Concentra Biosciences dated July 21, 2025. That historical item remains part of the company's published announcement record, while the active pipeline page emphasizes belrestotug, EOS-984 and EOS-215.

Pipeline milestones remain central

iTeos Therapeutics stock is best understood through the progress and timing of its clinical programs. The clearest operating markers are the active Phase 2 studies for belrestotug, the planned Phase 3 program and the earlier-stage studies for EOS-984 and EOS-215.